QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
$0.48
$0.31
$10.10
$6.88M4.16713,628 shsN/A
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
$0.02
$0.02
$0.01
$0.10
$1.10M1.67,445 shs13,640 shs
SPRCY
SciSparc
$4.00
-19.0%
$4.00
$2.75
$12.25
$4.15M-0.0810,035 shs12,500 shs
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
$0.22
$0.22
$0.08
$0.34
$56.90M2.65,474 shsN/A
Williston Holding Company, Inc. stock logo
WHCA
Williston
$0.01
$0.01
$0.01
$0.01
N/A1.64N/AN/A
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
0.00%0.00%0.00%0.00%0.00%
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
+23.31%+23.31%+23.31%+0.50%-34.10%
SPRCY
SciSparc
0.00%0.00%0.00%0.00%0.00%
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Williston Holding Company, Inc. stock logo
WHCA
Williston
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
SPRCY
SciSparc
N/AN/AN/AN/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Williston Holding Company, Inc. stock logo
WHCA
Williston
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
N/AN/AN/AN/A
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
N/AN/AN/AN/A
SPRCY
SciSparc
N/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/A
Williston Holding Company, Inc. stock logo
WHCA
Williston
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
$96.43M0.00N/AN/A$16.96 per share0.00
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
N/AN/AN/AN/AN/AN/A
SPRCY
SciSparc
N/AN/A$2.65 per share1.51$1.38 per shareN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
$7.38M7.71N/AN/AN/A
Williston Holding Company, Inc. stock logo
WHCA
Williston
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
-$157.19M-$17.72N/AN/AN/A-393.39%-101.29%-28.68%N/A
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
-$360K-$0.01N/AN/AN/AN/A-869.86%5/17/2024 (Estimated)
SPRCY
SciSparc
-$3.48M$14.940.27N/AN/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
-$18.79M-$0.08N/AN/A-254.66%-346.72%-94.54%N/A
Williston Holding Company, Inc. stock logo
WHCA
Williston
N/AN/A0.00N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
N/AN/AN/AN/AN/A
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
N/AN/AN/AN/AN/A
SPRCY
SciSparc
N/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/A
Williston Holding Company, Inc. stock logo
WHCA
Williston
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
1.11
1.03
0.72
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
N/A
0.01
0.01
SPRCY
SciSparc
N/A
11.05
2.25
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.64
1.35
0.90
Williston Holding Company, Inc. stock logo
WHCA
Williston
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
18.02%
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
N/A
SPRCY
SciSparc
N/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.02%
Williston Holding Company, Inc. stock logo
WHCA
Williston
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
29013.75 millionN/AOptionable
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
467.47 million46.83 millionNot Optionable
SPRCY
SciSparc
21.04 millionN/ANot Optionable
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
29258.62 millionN/ANot Optionable
Williston Holding Company, Inc. stock logo
WHCA
Williston
N/AN/AN/ANot Optionable

MLNT, WHCA, TRLPF, SPRCY, and NXEN Headlines

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Company Descriptions

Melinta Therapeutics logo

Melinta Therapeutics

NASDAQ:MLNT
Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.
Nexien BioPharma logo

Nexien BioPharma

OTCMKTS:NXEN
Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.

SciSparc

OTCMKTS:SPRCY
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to perform a pre-clinical study for the evaluation of SCI-210 drug development program for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv, Israel.
Acerus Pharmaceuticals logo

Acerus Pharmaceuticals

OTCMKTS:TRLPF
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.
Williston logo

Williston

OTCMKTS:WHCA
Williston Holding Company, Inc. owns and operates restaurants. The company was incorporated in 2012 and is based in Eden Prairie, Minnesota.